Ketamine

Generic Name
Ketamine
Brand Names
Ketalar
Drug Type
Small Molecule
Chemical Formula
C13H16ClNO
CAS Number
6740-88-1
Unique Ingredient Identifier
690G0D6V8H
Background

Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.

Indication

Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.

Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses. These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.

Associated Conditions
-
Associated Therapies
General Anesthesia, Induction and Maintenance of General Anesthesia

Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department

Early Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2022-02-01
Last Posted Date
2023-02-16
Lead Sponsor
Rady Children's Hospital, San Diego
Target Recruit Count
30
Registration Number
NCT05217706
Locations
🇺🇸

Rady Children's Hospital San Diego, San Diego, California, United States

Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder

Conditions
Interventions
First Posted Date
2022-01-26
Last Posted Date
2022-01-27
Lead Sponsor
Mclean Hospital
Target Recruit Count
20
Registration Number
NCT05209217
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

Dexamethasone & Ketamine as Adjuvants to Bupivacaine for Incisional Infiltration in Pediatric Abdominal Operations

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2022-01-13
Last Posted Date
2022-01-13
Lead Sponsor
Ain Shams University
Target Recruit Count
150
Registration Number
NCT05190952
Locations
🇪🇬

Ain Shams university hospitals, Cairo, Al Abbassia, Egypt

Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy

First Posted Date
2022-01-04
Last Posted Date
2022-01-04
Lead Sponsor
Ain Shams University
Target Recruit Count
90
Registration Number
NCT05176119
Locations
🇪🇬

Ain Shams university hospitals, Cairo, Al Abbassia, Egypt

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

First Posted Date
2021-12-14
Last Posted Date
2024-10-21
Lead Sponsor
Natalie Lockney
Target Recruit Count
64
Registration Number
NCT05156060
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Importance of Integrated Pulmonary Index in Pediatric Endoscopy

First Posted Date
2021-11-30
Last Posted Date
2023-02-28
Lead Sponsor
Marmara University
Target Recruit Count
60
Registration Number
NCT05137574
Locations
🇹🇷

Marmara University School of Medicine, Istanbul, Pendik, Turkey

Importance of Integrated Pulmonary Index in Pediatric Bronchoscopy

First Posted Date
2021-11-30
Last Posted Date
2023-02-28
Lead Sponsor
Marmara University
Target Recruit Count
60
Registration Number
NCT05137587
Locations
🇹🇷

Marmara University School of Medicine, Istanbul, Pendik, Turkey

Ketamine in Acute Brain Injury Patients.

Phase 4
Recruiting
Conditions
Interventions
First Posted Date
2021-10-28
Last Posted Date
2024-08-22
Lead Sponsor
Geert Meyfroidt, MD, PhD
Target Recruit Count
100
Registration Number
NCT05097261
Locations
🇧🇪

UZLeuven, Leuven, Belgium

🇧🇪

AZ Turnhout, Turnhout, Belgium

🇧🇪

CHU de Liège, Liège, Belgium

and more 5 locations

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients with Pancreatic Cancer

Early Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2021-10-20
Last Posted Date
2024-10-03
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
20
Registration Number
NCT05086250
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-09-20
Last Posted Date
2022-01-21
Lead Sponsor
Sage Therapeutics
Target Recruit Count
22
Registration Number
NCT05049343
Locations
🇺🇸

Sage Investigational Site, Newark, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath